Hillsdale Investment Management’s Axsome Therapeutics AXSM Stock Holding History

Hillsdale Investment Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.02M	Buy	+53,363	New	+$9.22M	0.25%	71

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hillsdale Investment Management's AXSM Position: Q1 2026 in Review

Hillsdale Investment Management opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 53,363 shares worth $9.02M. The stake represents 0.25% of the portfolio and ranks #71 among its holdings.

409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Hillsdale Investment Management held 53,363 shares of Axsome Therapeutics worth $9.02M as of Q1 2026.
Axsome Therapeutics was a new Hillsdale Investment Management position in Q1 2026.
Axsome Therapeutics made up 0.25% of Hillsdale Investment Management's portfolio in Q1 2026, its #71 holding.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.